References
- Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int. 2017;91(2):304–314.10.1016/j.kint.2016.08.030
- Laurence H, Beck JR. PLA2R and THSD7A: disparate paths to the same disease? J Am Soc Nephrol [Epub ahead of print].
- Palla R, Cirami C, Panichi V, et al. Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol. 1991;35:98–104.
- Yokoyama H, Goshima S, Wada T, et al. The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Nephrol Dial Transplant. 1999;14(10):2379–2386.10.1093/ndt/14.10.2379
- Filippone E, Farber J. Membranous nephropathy in the kidney allograft. Clin Transplant. 2016;30(11):1394–1402.10.1111/ctr.2016.30.issue-11
- Tran TH, Hughes JG, Greenfeld C, et al. Overview of current and alternative therapies for idiopathic membranous nephropathy. Pharmacotherapy. 2015;35(4):396–411.10.1002/phar.2015.35.issue-4
- Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535–542.10.1016/j.intimp.2005.11.015
- Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy. 2011;31(4):394–407.10.1592/phco.31.4.394
- Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369:2416–2423.10.1056/NEJMoa1304572
- Scharpé J, Maes B, Van Damme B. The podocyte: from bench to bedside. Acta Clinica Belgica. 2005;60(2):86–93.10.1179/acb.2005.016